Lesson plan

Ipsapirone

Ipsapirone ( , , ; developmental code names BAY Q 7821 and TVX Q 7821) is a selective 5-HT 1A receptor partial agonist of the arylpiperazine and azapirone families which was under development for the treatment of major depressive disorder and anxiety disorders but was never marketed. It is taken orally. The drug produces antidepressant-like, anxiolytic-like, and antiaggressive effects in rodents. It has been found to increase oxytocin levels in rodents, whereas findings in humans have been mixed. Ipsapirone produces adverse effects including vertigo, dizziness, and dysphoria in humans. Ipsapirone produces 1-(2-pyrimidinyl)piperazine (1-PP), a potent α 2 -adrenergic receptor antagonist, as an active metabolite. However, whereas 1-PP levels with buspirone are 8-fold higher than levels of buspirone itself, 1-PP is only a minor metabolite of ipsapirone constituting 2% of its exposure. Ipsapirone was first described in the scientific literature by 1984. It was developed by Bayer. The drug reached phase 3 clinical trials for treatment of major depressive disorder prior to the discontinuation of its development in 1997. It was also studied for treatment of generalized anxiety disorder.

Back to article

Article summary

Ipsapirone ( , , ; developmental code names BAY Q 7821 and TVX Q 7821) is a selective 5-HT 1A receptor partial agonist of the arylpiperazine and azapirone families which was under development for the treatment of major depressive disorder and anxiety disorders but was never marketed. It is taken orally. The drug produces antidepressant-like, anxiolytic-like, and antiaggressive effects in rodents. It has been found to increase oxytocin levels in rodents, whereas findings in humans have been mixed. Ipsapirone produces adverse effects including vertigo, dizziness, and dysphoria in humans. Ipsapirone produces 1-(2-pyrimidinyl)piperazine (1-PP), a potent α 2 -adrenergic receptor antagonist, as an active metabolite. However, whereas 1-PP levels with buspirone are 8-fold higher than levels of buspirone itself, 1-PP is only a minor metabolite of ipsapirone constituting 2% of its exposure. Ipsapirone was first described in the scientific literature by 1984. It was developed by Bayer. The drug reached phase 3 clinical trials for treatment of major depressive disorder prior to the discontinuation of its development in 1997. It was also studied for treatment of generalized anxiety disorder.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.